NEW YORK, Feb. 3 (GenomeWeb News) - Genome Therapeutics has set a price of $5.25 per share for the sale of up to 16.8 million shares of its common stock, the company said today.

The offering will fund the pending acquisition of Genesoft Pharmaceuticals, which was approved by the shareholders of both firms yesterday. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.